Aier Eye Hospital Group's (SZSE:300015) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
Aier Eye Hospital Group's (SZSE:300015) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
It hasn't been the best quarter for Aier Eye Hospital Group Co., Ltd. (SZSE:300015) shareholders, since the share price has fallen 14% in that time. Looking further back, the stock has generated good profits over five years. It has returned a market beating 96% in that time. Unfortunately not all shareholders will have held it for the long term, so spare a thought for those caught in the 45% decline over the last twelve months.
對於愛爾眼科醫院集團有限公司(深圳證券交易所代碼:300015)股東來說,這並不是最好的季度,因爲當時股價已經下跌了14%。再往前看,該股在五年內創造了可觀的利潤。在此期間,它的市場回報率已超過96%。不幸的是,並非所有股東都會長揸該股票,因此請多考慮那些在過去十二個月中跌幅爲45%的股東。
While this past week has detracted from the company's five-year return, let's look at the recent trends of the underlying business and see if the gains have been in alignment.
儘管過去一週減損了該公司的五年回報率,但讓我們來看看基礎業務的最新趨勢,看看漲幅是否一致。
Check out our latest analysis for Aier Eye Hospital Group
查看我們對愛爾眼科醫院集團的最新分析
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
雖然市場是一種強大的定價機制,但股價反映了投資者的情緒,而不僅僅是潛在的業務表現。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。
During five years of share price growth, Aier Eye Hospital Group achieved compound earnings per share (EPS) growth of 25% per year. The EPS growth is more impressive than the yearly share price gain of 14% over the same period. So it seems the market isn't so enthusiastic about the stock these days.
在五年的股價增長中,愛爾眼科醫院集團實現了每年25%的複合每股收益(EPS)增長。每股收益的增長比同期14%的年股價增長更令人印象深刻。因此,如今市場似乎對該股並不那麼熱情。
The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).
下圖顯示了 EPS 在一段時間內的跟蹤情況(如果你點擊圖片,你可以看到更多細節)。
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Dive deeper into the earnings by checking this interactive graph of Aier Eye Hospital Group's earnings, revenue and cash flow.
我們很高興地向大家報告,首席執行官的薪酬比資本相似公司的大多數首席執行官要適中。但是,儘管首席執行官的薪酬總是值得檢查的,但真正重要的問題是公司未來能否增加收益。查看這張愛爾眼科醫院集團收益、收入和現金流的互動圖表,深入了解收益。
What About Dividends?
分紅呢?
As well as measuring the share price return, investors should also consider the total shareholder return (TSR). The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Aier Eye Hospital Group, it has a TSR of 99% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!
除了衡量股價回報率外,投資者還應考慮股東總回報率(TSR)。基於股息再投資的假設,股東總回報率納入了任何分拆或貼現資本籌集的價值以及任何股息。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。就愛爾眼科醫院集團而言,在過去的5年中,其股東總回報率爲99%。這超過了我們之前提到的其股價回報率。這在很大程度上是其股息支付的結果!
A Different Perspective
不同的視角
While the broader market lost about 18% in the twelve months, Aier Eye Hospital Group shareholders did even worse, losing 45% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 15%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Before deciding if you like the current share price, check how Aier Eye Hospital Group scores on these 3 valuation metrics.
儘管整個市場在十二個月中下跌了約18%,但愛爾眼科醫院集團股東的表現甚至更糟,損失了45%(甚至包括股息)。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺15%。如果基本面數據繼續顯示長期可持續增長,那麼當前的拋售可能是一個值得考慮的機會。在決定是否喜歡當前股價之前,請查看愛爾眼科醫院集團在這三個估值指標上的得分。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.
如果你想看看另一家公司——一家財務狀況可能優異的公司——那麼千萬不要錯過這份已經證明自己可以增加收益的公司的免費名單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。